ACS chemical neuroscience molecule spotlight on RG1678

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


RG1678 is a glycine transporter-1 inhibitor currently in Phase III trials for the treatment of the negative symptoms of schizophrenia and is being developed by Roche (in combination with Chugai). Recent Phase II data shows that RG1678 is effective in reducing the negative symptoms when given in combination with second generation antipsychotics.

Original languageEnglish (US)
Pages (from-to)685-686
Number of pages2
JournalACS Chemical Neuroscience
Issue number12
StatePublished - Dec 21 2011
Externally publishedYes


  • GlyT1
  • RG1678
  • Schizophrenia
  • glycine transporter-1 inhibitor
  • negative symptoms

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology


Dive into the research topics of 'ACS chemical neuroscience molecule spotlight on RG1678'. Together they form a unique fingerprint.

Cite this